BRIDGEWATER, N.J., Dec. 9, 2010 /PRNewswire-FirstCall/ —
Sanofi-aventis (EURONEXT: SAN and NYSE:
SNY) announced today that the final survival analysis (10-year
follow-up) of the BCIRG001 study that included a Taxotere®
(docetaxel) Injection Concentrate chemotherapy treatment regimen in
the adjuvant breast cancer setting, as well as data from iniparib
(BSI-201) pre-clinical and clinical breast cancer studies will be
featured during the 33rd Annual San Antonio Breast Cancer Symposium
(SABCS) in San Antonio, Texas from December 8 to 12, 2010.
 

During SABCS, the final (10-year follow up) survival analysis of
the BCIRG001 study that included sanofi-aventis’ chemotherapy drug
Taxotere, in combination with doxorubicin and cyclophosphamide, in
women with operable node-positive breast cancer will be presented.
Also being presented are data from pre-clinical and clinical
studies involving the sanofi-aventis investigational compound
iniparib (BSI-201), which is being studied in breast cancer.
 Iniparib is a novel investigational small molecule with poly
(ADP-ribose) polymerase (PARP) inhibitory activity.

Key events at SABCS include: Taxotere Data:Abstract
#S4-3

Friday, Dec. 10

3:45 PM CSTAn oral presentation featuring final results from
the ten-year follow-up analysis of the BCIRG 001 trial Iniparib
Data:Abstract #P5-06-09

Phase 1b/2 MBC trial

Saturday, Dec. 11

5:30 – 7:30 PM CSTData from a Phase 1b study to assess the
safety and tolerability of the investigational compound iniparib
(BSI-201) in combination with irinotecan in patients with
metastatic breast cancer (MBC)Iniparib Data:Abstract #
P6-04-12

Activity in TNBC Cell lines

Sunday, Dec. 12

7:00 – 8:30 AM CSTData from a preclinical study assessing the
cell cycle effects of the investigational compound iniparib
(BSI-201) in combination

‘/>”/>

SOURCE